6ltk

Publication Abstract from PubMed

SNX-2112, as a promising anticancer lead compound targeting heat shock protein 90 (Hsp90), absence of complex crystal structure of Hsp90 (N) -SNX-2112 hindered further structural optimization and understanding on molecular interaction mechanism. Herein, a high-resolution complex crystal structure of Hsp90 (N) -SNX-2112 was successfully determined by X-ray diffraction, resolution limit, 2.14 A, PDB ID 6LTK, and their molecular interaction was analyzed in detail, which suggested that SNX-2112 was well accommodated in the ATP-binding pocket to disable molecular chaperone activity of Hsp90, therefore exhibiting favorable inhibiting activity on three non-small cell lung cancer (NSCLC) cell lines (IC50, 0.50 +/- 0.01 muM for A549, 1.14 +/- 1.11 muM for H1299, 2.36 +/- 0.82 muM for H1975) by inhibited proliferation, induced cell cycle arrest, and aggravated cell apoptosis. SNX-2112 exhibited high affinity and beneficial thermodynamic changes during the binding process with its target Hsp90 (N) confirmed by thermal shift assay (TSA, DeltaTm, and -9.51 +/- 1.00 degrees C) and isothermal titration calorimetry (K d , 14.10 +/- 1.60 nM). Based on the complex crystal structure and molecular interaction analysis, 32 novel SNX-2112 derivatives were designed, and 25 new ones displayed increased binding force with the target Hsp90 (N) verified by molecular docking evaluation. The results would provide new references and guides for anti-NSCLC new drug development based on the lead compound SNX-2112.

Complex Crystal Structure Determination and in vitro Anti-non-small Cell Lung Cancer Activity of Hsp90 (N) Inhibitor SNX-2112.,Zhao D, Xu YM, Cao LQ, Yu F, Zhou H, Qin W, Li HJ, He CX, Xing L, Zhou X, Li PQ, Jin X, He Y, He JH, Cao HL Front Cell Dev Biol. 2021 Mar 29;9:650106. doi: 10.3389/fcell.2021.650106., eCollection 2021. PMID:33855025^[3]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.